BenevolentAI founder returns as executive chairman amid leadership overhaul

18 October 2024

British artificial intelligence specialist BenevolentAI (AMS: BAI) has announced the return of its founder, Ken Mulvany, as executive chairman.

The move comes three years after Mr Mulvany stepped down as chairman and marks his return to the leadership team of the AI-focused drug discovery company he founded in 2013. Following the announcement, the company’s shares rose by about 10%.

The leadership changes follow a series of strategic decisions aimed at reshaping the firm, including two reductions in workforce levels in the past 18 months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK